系统综述与Meta分析:肝移植患者中新发非酒精性脂肪性肝病
该系统综述与Meta分析检索2017年3月前的医学数据库,纳入12项研究共2166例肝移植后活检患者,估算新发非酒精性脂肪性肝病(NAFLD)合并患病率为26%(95%CI 20%-31%),非酒精性脂肪性肝炎(NASH)为2%(95%CI 0%-3%),他克莫司相关NAFLD风险与环孢素相似(OR=1.02,95%CI 0.3-3.51)。
要点
- 肝移植后活检患者中新发NAFLD合并患病率为26%(95%CI 20%-31%)。
- 新发NASH合并患病率为2%(95%CI 0%-3%)。
- 他克莫司与环孢素的NAFLD风险相似(OR=1.02,95%CI 0.3-3.51)。
核心结论
- 肝移植患者易发生糖尿病、高血压或血脂异常,NAFLD可能在此背景下是重要因素。
- 本研究中NASH患病率趋于显著且与一般人群相似。
- 本研究提示NAFLD可能与特定移植指征相关,需进一步研究确认这些发现。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、MEDLINE/OVIDSP、Science Direct和EMBASE,检索时间为2017年3月。
- 纳入12项研究,共2166例接受肝移植后活检的受试者。
- 采用逆方差法计算比例/百分比的95%置信区间,并估算比值比(OR)及其95%置信区间。
主要发现
- 新发NAFLD的合并加权患病率为26%(95%CI 20%-31%)。
- 新发NASH的合并加权患病率为2%(95%CI 0%-3%)。
- 新发NAFLD患病率最高见于因酒精性肝硬化(37%)和隐源性肝硬化(35%)移植的患者以及服用他克莫司的患者(26%)。
- 他克莫司显示NAFLD风险与环孢素相似(OR=1.02,95%CI 0.3-3.51)。
局限性
- 需进一步研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: De novo non-alcoholic fatty liver disease (NAFLD) in liver-transplanted patients for cirrhosis not due to non-alcoholic steatohepatitis (NASH) is becoming a growing phenomenon. AIMS: We performed a systematic review and evaluated the prevalence of this event and possible associated factors. METHODS: A literature search in medical databases (PubMed, MEDLINE/OVIDSP, Science Direct and EMBASE) was performed in March 2017. Relevant publications were identified in most important databases. We estimated the pooled prevalence of NAFLD and NASH in patients with liver transplant. The data have been expressed as proportions/percentages, and 95% confidence intervals (CI) were calculated, using the inverse variance method. Odd ratios (OR) and 95% confidence intervals (95% CI) were estimated. RESULTS: Twelve studies were selected, enrolling 2166 subjects overall undergoing post-liver transplant biopsy. The pooled weighted prevalence of de novo NAFLD was 26% (95% CI 20%-31%). The pooled weighted prevalence of NASH was 2% (95% CI 0%-3%). The highest prevalences of de novo NAFLD were found for patients transplanted for alcoholic cirrhosis (37%) and cryptogenic cirrhosis (35%) and for patients taking tacrolimus (26%). Tacrolimus showed a risk of NAFLD similar to ciclosporin (OR = 1.02, 95% CI 0.3-3.51). CONCLUSIONS: Patients undergoing liver transplant are more prone to experience diabetes, hypertension or dyslipidaemia, and NAFLD may be an important element in this context. In this study, we show how the prevalence of NASH tends to remain significant and similar to the general population. Moreover, this study suggests a possible association with specific transplant indications. Further studies are required to confirm these findings.
引用
- Losurdo G, Castellaneta A, Rendina M, et al. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018. PMID: 29359341. doi:10.1111/apt.14521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。